Melanoma Abstracts ASCO 2015:

Overall survival in COMBI-d, a randomized, double-blinded, phase III study comparing the combination of dabrafenib (D) and trametinib (T) with dabrafenib and placebo (P) as first-line therapy in patients (pts) with unresectable or metastatic BRAF V600E/K mutation-positive cutaneous melanoma (First Author: Georgina V. Long)

Updated efficacy of the MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E-mutated (BRAFm) metastatic colorectal cancer (mCRC) (First Author: Chloe Evelyn Atreya)

Long-term follow up of survival in a randomized trial of wide or narrow excision margins in high-risk primary melanoma (First Author: Andrew J Hayes)

Surveillance imaging with fluorodeoxyglucose-positron emission tomography (FDG-PE) in the follow-up of melanoma patients at high risk of relapse (First Author: Jeremy Howard Lewin)

Clinical response, progression-free survival (PFS), and safety in patients (pts) with advanced melanoma (MEL) receiving nivolumab (NIVO) combined with ipilimumab (IPI) vs. IPI monotherapy in CheckMate 069 study (First Author: F. Stephen Hodi)

Long-term efficacy of pembrolizumab (pembro; MK-3475) in a pooled analysis of 655 patients (pts) with advanced melanoma (MEL) enrolled in KEYNOTE-001 (First Author: Adil Daud)